Exagen inc. partners with oregon's st. charles health system to offer avise® testing as an in-network benefit for patients suffering from debilitating autoimmune diseases

San diego, jan. 04, 2021 (globe newswire) -- exagen inc. (nasdaq: xgn), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today that all avise test offerings (ctd, lupus, sle prognostic, sle monitor, aps, vasculitis aav, mtx, and hcq) are a contracted in-network service with st. charles health system, the largest provider of medical care in central oregon.
XGN Ratings Summary
XGN Quant Ranking